Edward R. Conner, M.D. 

Edward R. Conner, M.D., is the Chief Medical Officer of Jade Biosciences. He brings more than 20 years of experience in clinical development, translational medicine and regulatory strategy, with deep expertise in immunology and the advancement of mechanism-based therapies across early- to late-stage programs. 

Prior to joining Jade, Dr. Conner served as Chief Medical Officer of Ardelyx, Inc. Prior to Ardelyx, Dr. Conner was Chief Medical Officer at Third Harmonic Bio. Previously, he was Chief Medical Officer at Locanabio. Earlier, he served as Site Lead and Division Head of Medical and Development at Astellas Gene Therapies (formerly Audentes Therapeutics). Prior to Astellas’ acquisition of Audentes, Dr. Conner was Chief Medical Officer and Senior Vice President of Audentes Therapeutics, where he led clinical development and operations, medical affairs, regulatory, drug safety and patient advocacy. Before Audentes, he served as Chief Medical Officer of Sangamo Therapeutics, where he advanced multiple clinical programs across gene therapy, genome editing and cell therapy.  

Earlier in his career, Dr. Conner was a Medical Director at Genentech, Inc. (a member of the Roche Group), where he led global clinical development programs for XOLAIR® (omalizumab) in chronic urticaria and allergic asthma.  

He earned his M.D. from the University of California, San Francisco, completed his residency in internal medicine at the University of Michigan and a fellowship in clinical immunology and allergic diseases at Johns Hopkins School of Medicine. He holds a B.S. in biology from Duke University. 

XOLAIR® is a registered trademark of Novartis AG.